1. Cancer Biology
  2. Cell Biology

Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion

  1. Elena Tomas Bort
  2. Megan Daisy Joseph
  3. Qiaoying Wang
  4. Edward Philip Carter
  5. Nicolas Jaime Roth
  6. Jessica Gibson
  7. Ariana Samadi
  8. Hemant M Kocher
  9. Sabrina Simoncelli
  10. Peter J McCormick  Is a corresponding author
  11. Richard Philip Grose  Is a corresponding author
  1. Queen Mary University of London, United Kingdom
  2. University College London, United Kingdom
https://doi.org/10.7554/eLife.86971
Share this article
Cite this article
  1. Elena Tomas Bort
  2. Megan Daisy Joseph
  3. Qiaoying Wang
  4. Edward Philip Carter
  5. Nicolas Jaime Roth
  6. Jessica Gibson
  7. Ariana Samadi
  8. Hemant M Kocher
  9. Sabrina Simoncelli
  10. Peter J McCormick
  11. Richard Philip Grose
(2023)
Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion
eLife 12:e86971.
https://doi.org/10.7554/eLife.86971
  2. Download BibTeX
  3. Download .RIS

Abstract

Pancreatic ductal adenocarcinoma (PDAC) continues to show no improvement in survival rates. One aspect of PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive therapeutic target. Mediated in part by highly druggable extracellular proteins, this axis plays essential roles in fibrosis, inflammation response and immune function. Analysing the main members of the PDAC extracellular purinome using publicly available databases discerned which members may impact patient survival. P2RY2 presents as the purinergic gene with the strongest association with hypoxia, the highest cancer cell-specific expression and the strongest impact on overall survival. Invasion assays using a 3D spheroid model revealed P2Y2 to be critical in facilitating invasion driven by extracellular ATP. Using genetic modification and pharmacological strategies we demonstrate mechanistically that this ATP-driven invasion requires direct protein-protein interactions between P2Y2 and αV integrins. DNA-PAINT super-resolution fluorescence microscopy reveals that P2Y2 regulates the amount and distribution of integrin αV in the plasma membrane. Moreover, receptor-integrin interactions were required for effective downstream signalling, leading to cancer cell invasion. This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential for therapeutic targeting.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file, or online resources are fully referenced.Human PDAC tumour data were generated by TCGA Research Network (https://www.cancer.gov/tcga) and by the Clinical Proteomic Tumour Analysis Consortium (https://www.proteomics.cancer.gov). The Genotype-Tissue Expression (GTEx) Project was used for the analysis of normal pancreatic tissue samples (https://gtexportal.org).

Article and author information

Author details

  1. Elena Tomas Bort

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7897-8891

  2. Megan Daisy Joseph

    London Centre for Nanotechnology, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8313-8467

  3. Qiaoying Wang

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

  4. Edward Philip Carter

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4499-1101

  5. Nicolas Jaime Roth

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

  6. Jessica Gibson

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

  7. Ariana Samadi

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

  8. Hemant M Kocher

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

  9. Sabrina Simoncelli

    London Centre for Nanotechnology, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7089-7667

  10. Peter J McCormick

    Centre for Endocrinology, Queen Mary University of London, London, United Kingdom
    For correspondence
    p.mccormick@qmul.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2225-5181

  11. Richard Philip Grose

    Centre for Tumour Biology, Queen Mary University of London, London, United Kingdom
    For correspondence
    r.p.grose@qmul.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4738-0173

Funding

Cancer Research UK (A27781)

  • Edward Philip Carter

Cancer Research UK (A25137)

  • Edward Philip Carter
  • Richard Philip Grose

Medical Research Council (MRC0227)

  • Elena Tomas Bort

Biotechnology and Biological Sciences Research Council (BB/T008709/1)

  • Megan Daisy Joseph

Royal Society (DHF\R1\191019)

  • Sabrina Simoncelli

Royal Society (RGS\R2\202038)

  • Sabrina Simoncelli

Medical Research Council (MR/N014308/1)

  • Nicolas Jaime Roth

Pancreatic Cancer Research Fund (Tissue Bank Grant)

  • Hemant M Kocher

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Tomas Bort et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,475
    views
  • 417
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elena Tomas Bort
  2. Megan Daisy Joseph
  3. Qiaoying Wang
  4. Edward Philip Carter
  5. Nicolas Jaime Roth
  6. Jessica Gibson
  7. Ariana Samadi
  8. Hemant M Kocher
  9. Sabrina Simoncelli
  10. Peter J McCormick
  11. Richard Philip Grose
(2023)
Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion
eLife 12:e86971.
https://doi.org/10.7554/eLife.86971

Share this article

https://doi.org/10.7554/eLife.86971

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    In vivo targeted and deterministic single-cell malignant transformation

    Pierluigi Scerbo, Benjamin Tisserand ... Bertrand Ducos
    Research Article

    Why does a normal cell possibly harboring genetic mutations in oncogene or tumor suppressor genes becomes malignant and develops a tumor is a subject of intense debate. Various theories have been proposed but their experimental test has been hampered by the unpredictable and improbable malignant transformation of single cells. Here, using an optogenetic approach we permanently turn on an oncogene (KRASG12V) in a single cell of a zebrafish brain that, only in synergy with the transient co-activation of a reprogramming factor (VENTX/NANOG/OCT4), undergoes a deterministic malignant transition and robustly and reproducibly develops within 6 days into a full-blown tumor. The controlled way in which a single cell can thus be manipulated to give rise to cancer lends support to the ‘ground state theory of cancer initiation’ through ‘short-range dispersal’ of the first malignant cells preceding tumor growth.

    1. Cancer Biology

    Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model

    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation

    Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction

    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.